KYMR: Kymera Therapeutics, Inc.
Performance
KYMR +136.72%
Watchlist
Select an item
Summary
KYMR at a glance
KYMR returned +136.72% over the past year and +16.37% a year over five years. Its worst drop in that year was -27.74%, smaller than 63% of stocks on Redstone, and its Sharpe ratio of 1.60 beats 94% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
51.56%
Actions
Metrics
Risk Indicators
Alpha91.57%
Beta0.94x
Sharpe1.60
Sortino3.29
Omega1.40
Calmar4.93
Martin8.16
Profile
About KYMR
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $11.9B
- Listed
- Aug 2020
- Employees
- 285
- Headquarters
- Watertown, MA
- Website
- kymeratx.com
Comparisons